HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine
DM Money, E Moses, S Blitz, SM Vandriel, N Lipsky… - Vaccine, 2016 - Elsevier
Objective To evaluate the immunogenicity and safety of the quadrivalent HPV (qHPV)
vaccine in HIV-positive women over 24 months. Design Between November 2008 and …
vaccine in HIV-positive women over 24 months. Design Between November 2008 and …
The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus
E McClymont, M Lee, J Raboud… - Clinical Infectious …, 2019 - academic.oup.com
Background Human papillomavirus (HPV) vaccination is safe and efficacious in women
without human immunodeficiency virus (HIV). Although good immunogenicity has been …
without human immunodeficiency virus (HIV). Although good immunogenicity has been …
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in girls living with HIV
J Brophy, A Bitnun, A Alimenti, N Lapointe… - The Pediatric …, 2018 - journals.lww.com
We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls
living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a …
living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a …
Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination
E McClymont, M Lee, J Raboud… - … of Gynecology & …, 2020 - Wiley Online Library
Objective To describe prevalent and persistent oncogenic human papillomavirus (HPV)
types detected in women living with HIV (WLWH) in Canada, including women with cervical …
types detected in women living with HIV (WLWH) in Canada, including women with cervical …
Brief report: persistence of non-vaccine oncogenic HPV genotypes in quadrivalent HPV-vaccinated women living with HIV
Background: Human papillomavirus (HPV) vaccines have promising safety and
immunogenicity data in women living with HIV (WLWH). However, it is critical to understand …
immunogenicity data in women living with HIV (WLWH). However, it is critical to understand …
Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV
E McClymont, G Ogilvie, A Albert, A Johnston… - Vaccine, 2020 - Elsevier
HPV vaccination schedules have changed as evidence has supported reduced dosing and
extended intervals. Women living with HIV (WLWH) represent an important population with …
extended intervals. Women living with HIV (WLWH) represent an important population with …
The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living with HIV
Background: Human papillomavirus (HPV) vaccination is safe and efficacious in women
without HIV. While good immunogenicity has been observed in women living with HIV …
without HIV. While good immunogenicity has been observed in women living with HIV …
Urinary symptoms and quality of life in women living with HIV: a cross-sectional study
Introduction and hypothesis To determine prevalence and quality of life impact of lower
urinary tract symptoms (LUTS) in women living with HIV (WLWH). Methods Cross-sectional …
urinary tract symptoms (LUTS) in women living with HIV (WLWH). Methods Cross-sectional …
Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV
E McClymont, AY Albert, C Wang… - … journal of STD & …, 2022 - journals.sagepub.com
Background Women living with HIV (WLWH) experience higher rates of human
papillomavirus (HPV) infection and cervical cancer than women without HIV. Changes in the …
papillomavirus (HPV) infection and cervical cancer than women without HIV. Changes in the …
Persistence of Non-Vaccine Oncogenic HPV Serotypes in Quadrivalent HPV2 Vaccinated Women Living with HIV
Objective: To describe prevalent and persistent oncogenic HPV types detected in women
living with HIV (WLWH) in Canada, including in women with cervical dyskaryosis, and to …
living with HIV (WLWH) in Canada, including in women with cervical dyskaryosis, and to …